KR20230100546A - Composition for Enhancing or Protecting Muscle Comprising Lactic Acid Bacteria from Kefir or Cultured Product Thereof - Google Patents
Composition for Enhancing or Protecting Muscle Comprising Lactic Acid Bacteria from Kefir or Cultured Product Thereof Download PDFInfo
- Publication number
- KR20230100546A KR20230100546A KR1020220044689A KR20220044689A KR20230100546A KR 20230100546 A KR20230100546 A KR 20230100546A KR 1020220044689 A KR1020220044689 A KR 1020220044689A KR 20220044689 A KR20220044689 A KR 20220044689A KR 20230100546 A KR20230100546 A KR 20230100546A
- Authority
- KR
- South Korea
- Prior art keywords
- kefir
- lactic acid
- muscle
- acid bacteria
- culture
- Prior art date
Links
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 title claims abstract description 180
- 241000894006 Bacteria Species 0.000 title claims abstract description 105
- 239000004310 lactic acid Substances 0.000 title claims abstract description 90
- 235000014655 lactic acid Nutrition 0.000 title claims abstract description 90
- 235000015141 kefir Nutrition 0.000 title claims abstract description 85
- 210000003205 muscle Anatomy 0.000 title claims abstract description 55
- 239000000203 mixture Substances 0.000 title abstract description 20
- 230000002708 enhancing effect Effects 0.000 title abstract description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 12
- 230000001681 protective effect Effects 0.000 claims abstract description 12
- 235000013376 functional food Nutrition 0.000 claims abstract description 11
- 208000001076 sarcopenia Diseases 0.000 claims abstract description 11
- 201000006938 muscular dystrophy Diseases 0.000 claims abstract description 9
- 241001468191 Lactobacillus kefiri Species 0.000 claims description 10
- 238000012258 culturing Methods 0.000 claims description 10
- 241000192130 Leuconostoc mesenteroides Species 0.000 claims description 9
- 239000005862 Whey Substances 0.000 claims description 5
- 102000007544 Whey Proteins Human genes 0.000 claims description 5
- 108010046377 Whey Proteins Proteins 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 235000020183 skimmed milk Nutrition 0.000 claims description 3
- 238000005728 strengthening Methods 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 24
- 230000004069 differentiation Effects 0.000 abstract description 21
- 210000001087 myotubule Anatomy 0.000 abstract description 18
- 201000000585 muscular atrophy Diseases 0.000 abstract description 15
- 206010028289 Muscle atrophy Diseases 0.000 abstract description 10
- 230000020763 muscle atrophy Effects 0.000 abstract description 10
- 230000012010 growth Effects 0.000 abstract description 5
- 230000001747 exhibiting effect Effects 0.000 abstract description 3
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 90
- 235000021314 Palmitic acid Nutrition 0.000 description 45
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 45
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 22
- 239000002953 phosphate buffered saline Substances 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 19
- 239000002609 medium Substances 0.000 description 18
- 210000000663 muscle cell Anatomy 0.000 description 15
- 101001023030 Toxoplasma gondii Myosin-D Proteins 0.000 description 14
- 102100040669 F-box only protein 32 Human genes 0.000 description 12
- 101710191029 F-box only protein 32 Proteins 0.000 description 12
- 235000013305 food Nutrition 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 210000000107 myocyte Anatomy 0.000 description 7
- 241000186660 Lactobacillus Species 0.000 description 6
- 241000192132 Leuconostoc Species 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 231100000135 cytotoxicity Toxicity 0.000 description 6
- 230000003013 cytotoxicity Effects 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 239000002207 metabolite Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 229940039696 lactobacillus Drugs 0.000 description 5
- 230000035800 maturation Effects 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 241000282414 Homo sapiens Species 0.000 description 4
- 238000000134 MTT assay Methods 0.000 description 4
- 208000029578 Muscle disease Diseases 0.000 description 4
- 238000011529 RT qPCR Methods 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 230000003833 cell viability Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000589220 Acetobacter Species 0.000 description 3
- 206010003694 Atrophy Diseases 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 231100000002 MTT assay Toxicity 0.000 description 3
- 208000029549 Muscle injury Diseases 0.000 description 3
- 102100038380 Myogenic factor 5 Human genes 0.000 description 3
- 101710099061 Myogenic factor 5 Proteins 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 239000003674 animal food additive Substances 0.000 description 3
- 230000037444 atrophy Effects 0.000 description 3
- 235000013339 cereals Nutrition 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 229940087559 grape seed Drugs 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 210000003098 myoblast Anatomy 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- 241000272517 Anseriformes Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 208000004930 Fatty Liver Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010019708 Hepatic steatosis Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 208000021642 Muscular disease Diseases 0.000 description 2
- 108010010416 Myogenic Regulatory Factors Proteins 0.000 description 2
- 102000015864 Myogenic Regulatory Factors Human genes 0.000 description 2
- 102100038379 Myogenic factor 6 Human genes 0.000 description 2
- 108010056785 Myogenin Proteins 0.000 description 2
- 102000004364 Myogenin Human genes 0.000 description 2
- 201000009623 Myopathy Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 230000003579 anti-obesity Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000015140 cultured milk Nutrition 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 208000010706 fatty liver disease Diseases 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000003999 initiator Substances 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 238000007431 microscopic evaluation Methods 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 230000037257 muscle growth Effects 0.000 description 2
- 108010084677 myogenic factor 6 Proteins 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 201000006935 Becker muscular dystrophy Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 206010012643 Diabetic amyotrophy Diseases 0.000 description 1
- 102100025014 E3 ubiquitin-protein ligase TRIM63 Human genes 0.000 description 1
- 101710164910 E3 ubiquitin-protein ligase TRIM63 Proteins 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 208000037149 Facioscapulohumeral dystrophy Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- 208000019331 Foodborne disease Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000235649 Kluyveromyces Species 0.000 description 1
- 241000194036 Lactococcus Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 201000009342 Limb-girdle muscular dystrophy Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010068836 Metabolic myopathy Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 201000002169 Mitochondrial myopathy Diseases 0.000 description 1
- 108010074084 Muscle Proteins Proteins 0.000 description 1
- 102000008934 Muscle Proteins Human genes 0.000 description 1
- 206010028311 Muscle hypertrophy Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 206010028643 Myopathy endocrine Diseases 0.000 description 1
- 206010028648 Myopathy toxic Diseases 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- 206010061533 Myotonia Diseases 0.000 description 1
- 208000010316 Myotonia congenita Diseases 0.000 description 1
- 206010068871 Myotonic dystrophy Diseases 0.000 description 1
- 208000023137 Myotoxicity Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 201000009110 Oculopharyngeal muscular dystrophy Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000006364 Torula Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- PFRQBZFETXBLTP-UHFFFAOYSA-N Vitamin K2 Natural products C1=CC=C2C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C(=O)C2=C1 PFRQBZFETXBLTP-UHFFFAOYSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- -1 and the like Proteins 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 201000011474 congenital myopathy Diseases 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 235000019543 dairy drink Nutrition 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 235000011850 desserts Nutrition 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 235000015071 dressings Nutrition 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 208000008570 facioscapulohumeral muscular dystrophy Diseases 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000013611 frozen food Nutrition 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000011868 grain product Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940087603 grape seed extract Drugs 0.000 description 1
- 235000002532 grape seed extract Nutrition 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000006278 hypochromic anemia Diseases 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 208000023692 inborn mitochondrial myopathy Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 229960002358 iodine Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229960003284 iron Drugs 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000001055 magnesium Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- DKHGMERMDICWDU-GHDNBGIDSA-N menaquinone-4 Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 DKHGMERMDICWDU-GHDNBGIDSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000012042 muscle hypertrophy Effects 0.000 description 1
- 230000036473 myasthenia Effects 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000021445 popular drink Nutrition 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000002363 skeletal muscle cell Anatomy 0.000 description 1
- 230000022379 skeletal muscle tissue development Effects 0.000 description 1
- 235000009561 snack bars Nutrition 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 208000002320 spinal muscular atrophy Diseases 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019143 vitamin K2 Nutrition 0.000 description 1
- 239000011728 vitamin K2 Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000001717 vitis vinifera seed extract Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/064—Saccharomycetales, e.g. baker's yeast
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/316—Foods, ingredients or supplements having a functional effect on health having an effect on regeneration or building of ligaments or muscles
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/155—Kefiri
-
- A23Y2220/47—
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Medical Informatics (AREA)
- Nutrition Science (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Alternative & Traditional Medicine (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
본 발명은 케피어 유래 유산균 또는 이의 배양물을 포함하는 근육 증강 또는 보호용 조성물에 관한 것이다.
본 발명에 따르면, 케피어 유래 유산균 또는 이의 배양물은 근섬유의 성장 및 근육 분화 인자 발현을 촉진하고, 근위축 인자의 발현을 감소시키는 효과를 나타낸다. 따라서, 본 발명의 조성물은 근육의 증강 또는 보호 효과를 나타내는 기능성 식품으로 사용될 수 있으며, 근감소증 또는 근위축증의 예방 또는 치료용 약학 조성물에 적용될 수 있다. The present invention relates to a composition for muscle enhancement or protection comprising kefir-derived lactic acid bacteria or a culture thereof.
According to the present invention, kefir-derived lactic acid bacteria or a culture thereof promotes the growth of muscle fibers and the expression of muscle differentiation factors, and exhibits the effect of reducing the expression of muscle atrophy factors. Therefore, the composition of the present invention can be used as a functional food exhibiting a muscle enhancing or protective effect, and can be applied to a pharmaceutical composition for preventing or treating sarcopenia or muscular dystrophy.
Description
본 발명은 케피어 유래 유산균 또는 이의 배양물을 포함하는 근육 증강 또는 보호용 조성물에 관한 것으로, 보다 상세하게는 케피어 유래 유산균 또는 이의 배양물을 포함하는 근육 증강 또는 보호용 기능성 식품 및 근감소증 또는 근위축증 예방 또는 치료용 약학 조성물에 관한 것이다.The present invention relates to a composition for muscle enhancement or protection comprising kefir-derived lactic acid bacteria or a culture thereof, and more particularly, to a functional food for muscle enhancement or protection comprising kefir-derived lactic acid bacteria or a culture thereof, and for preventing sarcopenia or muscular atrophy. Or a pharmaceutical composition for treatment.
골격근 세포는 근육분화(myogenesis) 과정을 통해 근육모세포(myoblast)에서 근섬유(myotube)로 성숙된다. 근육 분화는 MyoD, Myf5 등과 같은 근원성 조절 인자(myogenic regulatory factors, MRFs)에 의해서 조절되고, 분화 완료 후 근섬유의 직경과 길이가 증대되는 근육비대(muscle hypertrophy) 과정을 통해 근육의 크기가 증가된다. 골격근은 전체 몸무게의 50%에 달하는 가장 큰 기관으로, 근육 발달 능력 저하로 인한 근감소증(sarcopenia)은 신체능력을 저하시키고 낙상과 골절의 위험을 높이는 등 삶의 질에 큰 영향을 미치게 되므로, 근육의 증강 및 보호는 건강 관리에 있어서 매우 중요한 요소로 여겨지고 있다.Skeletal muscle cells mature from myoblasts to myotubes through myogenesis. Muscle differentiation is regulated by myogenic regulatory factors (MRFs) such as MyoD and Myf5, and after completion of differentiation, muscle size increases through the process of muscle hypertrophy, in which the diameter and length of muscle fibers increase. . Skeletal muscle is the largest organ, accounting for 50% of the total body weight, and sarcopenia due to reduced muscle development has a great impact on the quality of life, such as lowering physical ability and increasing the risk of falls and fractures. The enhancement and protection of the human body is regarded as a very important factor in health management.
한편, 케피어(Kefir)는 코카서스 산간 지방에서 유래한 발효유의 일종으로, 티벳지방 승려들이 건강을 위해 음용하던 것이 대중화된 음료이다. 케피어의 구성영양소로는 단백질 및 다당체가 포함되어 있고, 비타민 A, 비타민 B1, 비타민B2, 비타민B6, 비타민D, 비타민K2, 엽산, 니코틴산 및 칼슘, 철분, 요오드 등을 고루 포함하고 있다. 이러한 케피어는 유산균과 효모 복합체인 케피어 그레인으로 불리는 균종(케피어 과립균이라고도 한다)을 개시제로 하여 우유를 발효시켜 얻어진 요구르트상의 음료이다. On the other hand, kefir (Kefir) is a kind of fermented milk derived from the mountainous region of the Caucasus, and it is a popular drink that Tibetan monks drank for health. Constituent nutrients of kefir include protein and polysaccharide, and include vitamin A, vitamin B1, vitamin B2, vitamin B6, vitamin D, vitamin K2, folic acid, nicotinic acid, calcium, iron, and iodine. Such kefir is a yoghurt-like beverage obtained by fermenting milk using a lactic acid bacteria and yeast complex called kefir grain (also referred to as kefir granular bacteria) as an initiator.
케피어는 유산균(Lactobacillus, Lactococcus, Leuconostoc, Acetobacter, 및 Streptococcus 종), 초산균(Acetobacter 등) 및 효모(Saccharomyces, Kluyveromyces, Torula 및 Candida 종)를 포함하는 다양한 미생물을 함유하고 있으며 케피어는 항균활성, 항돌연변이성, 콜레스테롤 저하, 항비만성, 지방간 예방 등의 효과를 갖는 것으로 알려지고 있지만 근육 성장 촉진 및 근육 보호 활성은 보고된 바 없다.Kefir contains a variety of microorganisms, including lactobacilli (Lactobacillus, Lactococcus, Leuconostoc, Acetobacter, and Streptococcus species), acetobacters (such as Acetobacter), and yeasts (Saccharomyces, Kluyveromyces, Torula, and Candida species). It is known to have effects such as antimutagenicity, cholesterol lowering, antiobesity, and fatty liver prevention, but muscle growth promotion and muscle protection activities have not been reported.
예를 들어, 대한민국 공개특허 제10-2017-0115820호에서는 케피어를 유효성분으로 포함하는 식중독 예방 또는 치료용 조성물에 대해서 기재하고 있고, 대한민국 공개특허 제10-2019-0122636호에서는 케피어의 프로바이오틱 효과에 의한 반려동물의 변비와 관련된 장내의 지표 미생물의 감소 효과에 관해 기재하고 있지만 케피어의 근육 생성/보호 효과는 전혀 기재하고 있지 않다. For example, Korean Patent Publication No. 10-2017-0115820 describes a composition for preventing or treating food poisoning containing kefir as an active ingredient, and Korean Patent Publication No. 10-2019-0122636 describes kefir as an active ingredient. Although the effect of reducing intestinal indicator microorganisms related to constipation of companion animals due to the biotic effect is described, the muscle building/protection effect of kefir is not described at all.
또한, 케피어 유래 유산균, 초산균, 효모 등의 대사산물에 대한 활성 성분을 추출하여 보다 우수한 효능을 달성하기 위한 연구도 부족한 상황이다. 예를 들어, 대한민국 등록특허 제10-2037897호에서는 케피어 유래 유산균 및 포도씨 분말을 이용한 항비만 조성물을 기재하고 있고, 대한민국 등록특허 제10-2037898호에서는 케피어 유래 유산균과 포도씨 분말을 이용한 지방간 개선용 조성물을 기재하고 있으나, 케피어 유래 유산균을 그대로 이용하고 있어 활성 성분의 활용에 대한 개선의 여지가 남아 있다. In addition, there is a lack of research to achieve better efficacy by extracting active ingredients for metabolites such as kefir-derived lactic acid bacteria, acetic acid bacteria, and yeast. For example, Korean Patent Registration No. 10-2037897 describes an anti-obesity composition using kefir-derived lactic acid bacteria and grape seed powder, and Korean Patent Registration No. 10-2037898 improves fatty liver using kefir-derived lactic acid bacteria and grape seed powder. Although the composition for use is described, kefir-derived lactic acid bacteria are used as they are, so there remains room for improvement in the utilization of active ingredients.
본 발명의 발명자들은 케피어 유래 유산균 또는 이를 배양시켜 얻은 배양물을 손상된 근육세포에 처리한 결과 근섬유의 성장 및 근육 분화 인자 발현이 촉진되고 근육 위축 인자의 발현이 감소되는 효과, 즉 근육의 증강 및 보호 효과가 나타난다는 것을 발견하고, 본 발명을 완성하였다.The inventors of the present invention treat kefir-derived lactic acid bacteria or cultures obtained by culturing them on damaged muscle cells, resulting in the growth of muscle fibers and the expression of muscle differentiation factors being promoted and the expression of muscle atrophy factors being reduced, that is, muscle enhancement and It was found that a protective effect was exhibited, and the present invention was completed.
본 발명의 목적은 케피어 유래 유산균 또는 이의 배양물을 포함하는 근육 증강 또는 보호용 기능성 식품을 제공하는 것이다.An object of the present invention is to provide a functional food for muscle enhancement or protection comprising kefir-derived lactic acid bacteria or a culture thereof.
본 발명의 다른 목적은 케피어 유래 유산균 또는 이의 배양물을 포함하는 근감소증 또는 근위축증의 예방 또는 치료용 약학 조성물을 제공하는 것이다.Another object of the present invention is to provide a pharmaceutical composition for the prevention or treatment of sarcopenia or muscular dystrophy comprising kefir-derived lactic acid bacteria or a culture thereof.
상기 목적을 달성하기 위하여, 본 발명은 케피어 유래 유산균 또는 이의 배양물을 포함하는 근육 증강 또는 보호용 기능성 식품을 제공한다.In order to achieve the above object, the present invention provides a functional food for muscle enhancement or protection comprising kefir-derived lactic acid bacteria or a culture thereof.
본 발명에서, 상기 케피어 유래 유산균은 락토바실러스 케피어리(Lactobacillus kefiri) 및 류코노스톡 메센테로이데스(Leuconostoc mesenteroides)로부터 선택된 1종 이상일 수 있다.In the present invention, the kefir-derived lactic acid bacteria may be at least one selected from Lactobacillus kefiri and Leuconostoc mesenteroides .
본 발명에서, 상기 배양물은 케피어 유래 유산균을 배지에 접종한 후 배양하고 균체를 제거하여 수득한 것일 수 있다.In the present invention, the culture may be obtained by inoculating kefir-derived lactic acid bacteria into a medium and then culturing and removing the cells.
본 발명에서, 상기 배지는 MRS (Man Rogosa Sharpe), GAM (Gifu Anaerobic Medium), 유청 및 탈지유로 구성된 군에서 선택된 1종 이상의 배지를 포함할 수 있다.In the present invention, the medium may include at least one medium selected from the group consisting of Man Rogosa Sharpe (MRS), Gifu Anaerobic Medium (GAM), whey, and skim milk.
본 발명은 또한, 케피어 유래 유산균 또는 이의 배양물을 포함하는 근감소증 또는 근위축증의 예방 또는 치료용 약학 조성물을 제공한다.The present invention also provides a pharmaceutical composition for the prevention or treatment of sarcopenia or muscular dystrophy comprising kefir-derived lactic acid bacteria or a culture thereof.
본 발명에 따르면, 케피어 유래 유산균 또는 이의 배양물은 근섬유의 성장 및 근육 분화 인자 발현을 촉진하고, 근육 위축 인자의 발현을 감소시키는 효과를 나타낸다. 따라서, 케피어 유래 유산균 또는 이의 배양물은 근육의 증강 및 보호 효과를 나타내는 기능성 식품으로 사용될 수 있으며, 근감소 또는 근위축성 질환의 예방 또는 치료용 약학 조성물에 사용될 수 있다. 또한, 본 발명에 따르면 케피어 유래 유산균뿐만 아니라 이의 대사산물로도 매우 우수한 효과를 나타낼 수 있기 때문에 생균 사용 시 일정 균 수 이상을 유지하여야 하는 제약 없이 사용이 가능하다.According to the present invention, kefir-derived lactic acid bacteria or cultures thereof promote the growth of muscle fibers and the expression of muscle differentiation factors, and exhibit effects of reducing the expression of muscle atrophy factors. Therefore, kefir-derived lactic acid bacteria or a culture thereof may be used as a functional food exhibiting muscle enhancement and protective effects, and may be used in a pharmaceutical composition for preventing or treating muscle loss or amyotrophic disease. In addition, according to the present invention, since not only kefir-derived lactic acid bacteria but also their metabolites can exhibit very excellent effects, they can be used without restrictions requiring maintaining a certain number of bacteria or more when using live bacteria.
도 1은 본 발명의 일 실시예에 따른 C2C12 분화 및 샘플 처리 실험 절차를 나타낸 것이다.
도 2는 팔미트산 농도에 따른 세포독성 결과를 나타낸 것이다.
도 3은 케피어 유래 유산균의 농도에 따른 세포독성 결과를 나타낸 것이다.
도 4는 본 발명의 일 실시예에 따른 유산균 샘플을 근육세포에 처리한 후 촬영한 현미경 사진을 나타낸 것이다.
도 5는 본 발명의 일 실시예에 따른 유산균 샘플을 근육세포에 처리한 후 근섬유의 수, 길이 및 직경 측정 결과를 나타낸 그래프이다.
도 6은 본 발명의 일 실시예에 따른 유산균 샘플을 근육세포에 처리한 후 MyoD의 발현양을 나타낸 것이다.
도 7은 본 발명의 일 실시예에 따른 유산균 샘플을 근육세포에 처리한 후 Atrogin-1의 발현양을 나타낸 것이다.
도 8은 본 발명의 일 실시예에 따른 유산균 배양물 샘플을 근육세포에 처리한 후 촬영한 현미경 사진을 나타낸 것이다.
도 9는 본 발명의 일 실시예에 따른 유산균 배양물 샘플을 근육세포에 처리한 후 근섬유의 수, 길이 및 직경 측정 결과를 나타낸 그래프이다.
도 10은 본 발명의 일 실시예에 따른 유산균 배양물 샘플을 근육세포에 처리한 후 MyoD의 발현양을 나타낸 것이다.
도 11은 본 발명의 일 실시예에 따른 유산균 배양물 샘플을 근육세포에 처리한 결과 Atrogin-1의 발현양을 나타낸 것이다.Figure 1 shows the experimental procedure for C2C12 differentiation and sample processing according to an embodiment of the present invention.
Figure 2 shows the cytotoxicity results according to palmitic acid concentration.
Figure 3 shows the cytotoxicity results according to the concentration of kefir-derived lactic acid bacteria.
Figure 4 shows a photomicrograph taken after treating a lactic acid bacteria sample according to an embodiment of the present invention to muscle cells.
5 is a graph showing the results of measuring the number, length, and diameter of muscle fibers after treating muscle cells with lactic acid bacteria samples according to an embodiment of the present invention.
Figure 6 shows the expression level of MyoD after processing a lactic acid bacteria sample according to an embodiment of the present invention to muscle cells.
Figure 7 shows the expression level of Atrogin-1 after processing a lactic acid bacteria sample according to an embodiment of the present invention to muscle cells.
8 shows a photomicrograph taken after treating a lactic acid bacteria culture sample according to an embodiment of the present invention to muscle cells.
9 is a graph showing the results of measuring the number, length, and diameter of muscle fibers after treating muscle cells with lactic acid bacteria culture samples according to an embodiment of the present invention.
10 shows the expression level of MyoD after treatment of a lactic acid bacteria culture sample to muscle cells according to an embodiment of the present invention.
Figure 11 shows the expression level of Atrogin-1 as a result of treating muscle cells with lactic acid bacteria culture samples according to an embodiment of the present invention.
다른 식으로 정의되지 않는 한, 본 명세서에서 사용된 모든 기술적 및 과학적 용어들은 본 발명이 속하는 기술 분야에서 숙련된 전문가에 의해서 통상적으로 이해되는 것과 동일한 의미를 갖는다. 일반적으로, 본 명세서에서 사용된 명명법은 본 기술 분야에서 잘 알려져 있고 통상적으로 사용되는 것이다.Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. In general, the nomenclature used herein is one well known and commonly used in the art.
본 발명은 케피어 유래 유산균 또는 이의 배양물의 근육 증강 및 보호 활성에 관한 것이다.The present invention relates to muscle enhancing and protective activities of kefir-derived lactic acid bacteria or cultures thereof.
본 발명에서, 케피어 유래 유산균 또는 이의 배양물은 근섬유의 성장 및 근육 분화 인자 발현을 촉진하고, 근육 위축 인자의 발현을 감소시키는 효과를 나타낸다. 따라서, 케피어 유래 유산균 또는 이의 배양물은 식품에 적용되어 근육의 증강 및 보호 효과를 나타낼 수 있을 뿐만 아니라, 근손상으로부터 근육을 보호하고 회복시키는 효과를 통해 근감소 또는 근위축성 질환의 예방 또는 치료용 약학 조성물로도 사용될 수 있다. 또한, 본 발명에 따르면 케피어 유래 유산균의 대사산물로도 매우 우수한 효과를 나타낼 수 있기 때문에 생균 사용 시 발생하는 균 수 유지의 제약 없이 사용될 수 있다.In the present invention, kefir-derived lactic acid bacteria or a culture thereof promotes the growth of muscle fibers and the expression of muscle differentiation factors, and exhibits effects of reducing the expression of muscle atrophy factors. Therefore, kefir-derived lactic acid bacteria or cultures thereof can be applied to food to exhibit muscle enhancement and protective effects, as well as prevent or treat muscle loss or muscle atrophy through the effect of protecting and recovering muscles from muscle damage. It can also be used as a pharmaceutical composition for use. In addition, according to the present invention, since metabolites of kefir-derived lactic acid bacteria can exhibit very excellent effects, they can be used without restrictions on maintaining the number of bacteria that occur when using live bacteria.
본 발명에서, 케피어(kefir)는 코카서스 산간 지방에서 유래한 발효유의 일종으로, 케피어는 유산균과 효모 복합체인 케피어 그레인으로 불리우는 균종을 개시제로 하여 우유를 발효시켜 얻어진 요구르트상의 음료를 의미한다.In the present invention, kefir is a type of fermented milk derived from the mountainous region of the Caucasus, and kefir refers to a yogurt-like beverage obtained by fermenting milk using a strain called kefir grain, which is a complex of lactic acid bacteria and yeast, as an initiator. .
본 발명에서, 케피어 유래 유산균은 락토바실러스 케피어리(Lactobacillus kefiri) 및 류코노스톡 메센테로이데스(Leuconostoc mesenteroides)로부터 선택된 1종 이상일 수 있다.In the present invention, the kefir-derived lactic acid bacteria may be at least one selected from Lactobacillus kefiri and Leuconostoc mesenteroides .
바람직하게, 본 발명에서 적용 가능한 케피어 유래 유산균은 락토바실러스 케피어리 DH1, 락토바실러스 케피어리 DH3, 락토바실러스 케피어리 DH5, 류코노스톡 메센테로이데스 DH1604(LCM4), 류코노스톡 메센테로이데스 DH1606, 류코노스톡 메센테로이데스 DH1607, 류코노스톡 메센테로이데스 DH1608(LCM8) 및 류코노스톡 메센테로이데스 DH1609로부터 선택된 1종 이상이다. 이 중, 락토바실러스 케피어리 DH5는 한국미생물보존센터에 수탁번호 KCCM11837P(수탁일자: 2016년 4월 29일)로 기탁되어 있고, 류코노스톡 메센테로이데스 DH1604는 한국미생물보존센터에 수탁번호 KCCM12117P(수탁일자: 2017년 9월 21일)로 기탁되어 있으며, 류코노스톡 메센테로이데스 DH1608은 한국생명공학연구원에 수탁번호 KCTC18854P(수탁일자: 2020년 10월 16일)로 기탁되어 있다. Preferably, kefir-derived lactic acid bacteria applicable in the present invention are Lactobacillus kefir DH1, Lactobacillus kefir DH3, Lactobacillus kefir DH5, Leuconostoc mesenteroides DH1604 (LCM4), Leuconostoc mesenteroides DH1606, It is at least one selected from Leuconostoc mecenteroides DH1607, Leuconostoc mecenteroides DH1608 (LCM8) and Leuconostoc mecenteroides DH1609. Among them, Lactobacillus kefirii DH5 has been deposited with the Korea Microbial Conservation Center under the accession number KCCM11837P (date of accession: April 29, 2016), and Leuconostoc mecenteroides DH1604 has been deposited with the Korea Microorganism Conservation Center under the accession number KCCM12117P ( Accession date: September 21, 2017), and Leuconostoc mecenteroides DH1608 has been deposited with the Korea Research Institute of Bioscience and Biotechnology under the accession number KCTC18854P (accession date: October 16, 2020).
본 발명에서, 케피어 유래 유산균은 생균 또는 생균을 처리한 것, 예를 들어 생균을 사균화 시킨 것을 포함하는 의미이다. 예를 들어, 유산균의 안정성을 확보하기 위해 생균에 열, 방사선 등을 처리하여 사균화시킨 것을 이용할 수 있다.In the present invention, kefir-derived lactic acid bacteria is meant to include live bacteria or those treated with live bacteria, for example, those obtained by killing live bacteria. For example, in order to secure the stability of lactic acid bacteria, viable bacteria can be killed by treating them with heat, radiation, or the like.
또한, 케피어 유래 유산균의 배양물이란 케피어 유래 유산균을 배지에 접종하고 배양 또는 발효시켜 얻을 수 있으며, 배양 과정에서 생성된 대사산물을 포함하는 의미로 해석될 수 있다. 구체적으로, 상기 배양물은 균주; 균주를 배지에 배양한 후 생성된 배양액; 배양액의 상등액, 농축액 또는 희석액; 배양액의 건조물 또는 정제물; 또는 이들의 혼합물을 포함할 수 있다. 예를 들어, 본 발명의 배양물은 균주를 배지에 배양하여 수득한 배양액 또는 이로부터 균체를 제거한 것일 수 있다. 또한, 배양물을 여과, 동결건조 등 후처리하여 사용하는 것도 가능하다.In addition, the culture of kefir-derived lactic acid bacteria can be obtained by inoculating kefir-derived lactic acid bacteria in a medium and culturing or fermenting, and can be interpreted as including metabolites produced during the culturing process. Specifically, the culture is a strain; Culture medium produced after culturing the strain in a medium; supernatants, concentrates or dilutions of cultures; dried or purified products of the culture; or mixtures thereof. For example, the culture of the present invention may be a culture solution obtained by culturing a strain in a medium, or a culture solution obtained by removing cells therefrom. In addition, it is also possible to use the culture after post-treatment such as filtration or freeze-drying.
본 발명에서, 케피어 유래 유산균을 배양하는 배지로는 탄소원, 질소원, 무기염류 등을 함유하고 유산균의 배양을 효율적으로 수행할 수 있는 배지를 사용할 수 있다. 예를 들어, MRS (Man Rogosa Sharpe), GAM (Gifu Anaerobic Medium), 유청, 탈지유 등의 배지를 사용할 수 있으며, 포도씨 분말, 포도씨 추출물 등의 프리바이오틱스; 또는 이스트, 덱스트로스 등의 첨가제를 1종 이상 첨가하여 사용할 수 있다. 본 발명에서, 배지가 유청을 포함하는 경우 케피어 유래 유산균의 대사 과정에서 근육 증강 및 보호 활성이 우수한 물질이 생성되어, 대사산물로도 우수한 효과를 나타낼 수 있다는 측면에서 바람직하다.In the present invention, as a medium for culturing kefir-derived lactic acid bacteria, a medium containing a carbon source, a nitrogen source, inorganic salts, etc. and capable of efficiently culturing lactic acid bacteria may be used. For example, media such as MRS (Man Rogosa Sharpe), GAM (Gifu Anaerobic Medium), whey, and skim milk may be used, and prebiotics such as grape seed powder and grape seed extract; Alternatively, one or more additives such as yeast and dextrose may be added and used. In the present invention, when the medium contains whey, it is preferable in that a substance having excellent muscle building and protective activity is produced during the metabolic process of kefir-derived lactic acid bacteria, so that metabolites can also exhibit excellent effects.
본 발명에서, 상기 케피어 유래 유산균은 배지에 대해 1 x 102 내지 1 x 1012 CFU/ml, 바람직하게는 1 x 104 내지 1 x 1010 CFU/ml의 양으로 접종될 수 있으며, 배양은 10 내지 200시간, 바람직하게는 24시간 내지 120시간 동안 수행될 수 있다. 유산균의 양이 많은 경우 배양 시간을 줄이고, 양이 적은 경우에는 배양 시간을 늘려, 이로부터 생산되는 대사산물의 양을 조절할 수 있다.In the present invention, the kefir-derived lactic acid bacteria may be inoculated in an amount of 1 x 10 2 to 1 x 10 12 CFU/ml, preferably 1 x 10 4 to 1 x 10 10 CFU/ml, and cultured. may be carried out for 10 to 200 hours, preferably 24 hours to 120 hours. The amount of metabolites produced therefrom can be controlled by reducing the culture time when the amount of lactic acid bacteria is large and increasing the culture time when the amount is small.
본 발명의 일 실시 형태에서, 상기 배양물은 배양액을 원심분리하여 수득한 상등액일 수 있다. 상기 원심분리는, 1,000 내지 5,000 x g, 구체적으로 2,000 내지 4,000 x g의 속도로, 1분 내지 1시간, 구체적으로 5분 내지 30분 수행될 수 있다.In one embodiment of the present invention, the culture may be a supernatant obtained by centrifuging the culture medium. The centrifugation may be performed at a speed of 1,000 to 5,000 x g , specifically 2,000 to 4,000 x g for 1 minute to 1 hour, specifically 5 minutes to 30 minutes.
본 발명에서, 케피어 유래 유산균은 사균체나 이의 배양물로도 우수한 근육 성장 및 보호 효과를 나타낼 수 있는 바, 생균과 같이 일정 균 수 이상을 유지하여야 하는 제약 없이 효과를 발휘할 수 있으며, 제조 및 보관 시 편의성이 보장될 수 있으므로 바람직하다.In the present invention, kefir-derived lactic acid bacteria can exhibit excellent muscle growth and protective effects even with dead cells or their culture, so they can exert their effects without the constraint of maintaining a certain number of bacteria or more like live bacteria, manufacturing and This is preferable because convenience can be guaranteed during storage.
본 발명에 따른 케피어 유래 유산균 또는 이의 배양물은 근섬유의 성장 및 근육 분화 인자 발현을 촉진하고 근육 위축 인자의 발현을 감소시키는 효과를 나타낸다. Kefir-derived lactic acid bacteria or a culture thereof according to the present invention exhibits the effect of promoting the growth of muscle fibers and the expression of muscle differentiation factors and reducing the expression of muscle atrophy factors.
근육 분화 인자는 근아세포의 증식 및 근관세포로의 분화를 유도하는 인자로서, 대표적으로 MyoD, Myf5, myogenin, MRF4 등이 있다. 구체적으로, MyoD, Myf5 등에 의해 근아세포로의 결정, 증식 및 유지가 제어되고, 하류인자로서 myogenin, MRF4 등이 작용하여 근관세포로의 분화, 성숙을 제어한다. 이중 MyoD는 근육 관련 유전자의 발현을 유지하기 위해 반드시 필요하기 때문에 MyoD는 근육의 분화 및 성숙의 마커로 사용될 수 있다.The muscle differentiation factor is a factor that induces the proliferation of myoblasts and differentiation into myotubes, and representatively includes MyoD, Myf5, myogenin, MRF4 and the like. Specifically, determination, proliferation, and maintenance of myoblasts are controlled by MyoD, Myf5, and the like, and myogenin, MRF4, and the like act as downstream factors to control differentiation and maturation into myotubes. Among them, MyoD can be used as a marker of muscle differentiation and maturation because MyoD is essential for maintaining the expression of muscle-related genes.
근육 위축 인자는 근섬유의 무게 및 부피 감소 및 근육 단백질의 분해에 관여하는 인자로서 Atrogin-1, MuRF-1 등이 있다. 이 중 Atrogin-1은 파열된 근세포에서 나온 염증성 물질에 의해 합성이 증가되고 단백질 분해를 유도함으로써 근육 위축을 야기하는 것으로, Atrogin-1의 발현을 저해하는 경우 근위축 또는 근감소 억제 효과를 기대할 수 있다. Muscle atrophy factors are factors involved in weight and volume reduction of muscle fibers and degradation of muscle proteins, such as Atrogin-1 and MuRF-1. Among them, Atrogin-1 causes muscle atrophy by increasing its synthesis by inflammatory substances from ruptured myocytes and inducing protein degradation. Inhibiting the expression of Atrogin-1 can be expected to inhibit muscle atrophy or muscle loss. there is.
이와 같이, 근육 분화 인자의 발현 촉진 및 근육 위축 인자의 발현 억제에 따라, 근육의 증강, 보호 및 회복 효과가 발휘될 수 있다. 본 발명의 실시예에서는, 근위축이 유도된 세포에 케피어 유래 유산균 또는 이의 배양물을 처리한 결과 근육 분화 인자인 MyoD의 발현량이 증가되고 Atrogin-1의 발현량이 감소하는 것을 확인하였으며, 생성되는 근섬유의 수, 길이 및 지름이 증가하는 것을 확인하였다.In this way, according to the promotion of muscle differentiation factor expression and the suppression of the expression of muscle atrophy factor, muscle enhancement, protection and recovery effects can be exerted. In an embodiment of the present invention, it was confirmed that the expression level of MyoD, a muscle differentiation factor, increased and the expression level of Atrogin-1 decreased as a result of treating the cells in which muscular atrophy was induced with kefir-derived lactic acid bacteria or a culture thereof. It was confirmed that the number, length and diameter of muscle fibers increased.
따라서, 본 발명의 케피어 유래 유산균 또는 이의 배양물은 근육의 증강 및 보호 효과를 나타내는 기능성 식품에 적용될 수 있을 뿐만 아니라, 근육 질환의 예방 또는 치료용 약학 조성물로도 사용될 수 있다.Therefore, the kefir-derived lactic acid bacteria or culture thereof of the present invention can be applied to functional foods exhibiting muscle enhancing and protective effects, and can also be used as a pharmaceutical composition for preventing or treating muscle diseases.
이에 따라, 본 발명은 또한, 케피어 유래 유산균 또는 이의 배양물을 포함하는 기능성 식품을 제공한다.Accordingly, the present invention also provides a functional food containing kefir-derived lactic acid bacteria or a culture thereof.
구체적으로, 본 발명에 따른 케피어 유래 유산균 또는 이의 배양물을 식품에 적용하면 섭취 시 근육 증강 및 보호 효과가 발휘되어 건강을 증진시킬 수 있다.Specifically, when the kefir-derived lactic acid bacteria or culture thereof according to the present invention is applied to food, muscle strengthening and protective effects are exhibited when ingested, thereby improving health.
상기 식품은 음료, 껌, 차, 비타민 복합제, 건강보조 식품류일 수 있으며, 더욱 자세히는, 유제품, 제과물, 조미료, 음료 및 드링크제, 스낵, 캔디류, 젤리류, 아이스크림 및 냉동용 디저트, 아침 곡물류, 영양바, 스낵 바 초콜렛 제품, 가공 식품, 곡물 제품 및 파스타, 스프, 소스 및 드레싱, 과자 제품, 오일 및 지방 제품, 유제품 음료 (dairy drink) 및 우유 음료, 차, 두유 및 콩 유제품 (soy dairy-like product), 냉동식품, 조리 음식 및 대체 음식, 육류 제품, 치즈, 요구르트, 빵 및 롤빵, 케이크, 쿠키 및 크래커로 이루어진 군에서 선택된 어느 하나일 수 있다. The food may be beverages, gum, tea, vitamin complexes, health supplements, and more specifically, dairy products, confectionery products, seasonings, beverages and drinks, snacks, candies, jellies, ice cream and frozen desserts, breakfast grains, Nutrition bars, snack bars Chocolate products, processed foods, grain products and pastas, soups, sauces and dressings, confectionery products, oil and fat products, dairy drinks and milk drinks, tea, soy dairy- like product), frozen food, cooked food and alternative food, meat products, cheese, yogurt, bread and rolls, cakes, cookies and crackers.
본 발명의 식품은 사람뿐만 아니라 동물용 식품 및 사료 첨가제를 포함하는 의미일 수 있다. 상기 동물은 개, 고양이, 소, 돼지, 양, 염소, 사슴, 닭, 오리, 거위, 꿩 등을 포함할 수 있다. 또한, 용어 "사료 첨가제"는 가축의 생산성 향상, 반려동물의 건강을 증진 및/또는 유지시키거나 신체 컨디션 유지를 위하여 사료에 첨가되는 물질을 의미한다. 본 발명의 케피어 유래 유산균의 배양물을 동물용 식품 및 사료 첨가제에 이용하면, 근육 증강 및 보호 효과를 통해 동물의 건강 상태를 개선할 수 있다.The food of the present invention may be meant to include food and feed additives for humans as well as animals. The animal may include dogs, cats, cows, pigs, sheep, goats, deer, chickens, ducks, geese, pheasants, and the like. In addition, the term "feed additive" means a substance added to feed to improve livestock productivity, promote and/or maintain companion animal health, or maintain physical condition. When the culture of the kefir-derived lactic acid bacteria of the present invention is used in food and feed additives for animals, it is possible to improve the health of animals through muscle strengthening and protective effects.
또한, 본 발명은 케피어 유래 유산균 또는 이의 배양물을 포함하는 근육 질환의 예방 또는 치료용 약학 조성물을 제공할 수 있다.In addition, the present invention may provide a pharmaceutical composition for the prevention or treatment of muscle diseases comprising kefir-derived lactic acid bacteria or a culture thereof.
본 발명에서, 상기 근육 질환은 근감소증 또는 근위축증일 수 있다. 본 발명에서, 상기 근감소증 또는 근위축증은 사전적인 의미의 근감소증(sarcopenia) 또는 근위축증(muscular atrophy) 뿐만 아니라, 근감소 또는 근위축을 유발하거나 이로부터 유도되는 근육 질환, 예를 들어 근감소성 비만(sarcopenic obesity), 근육병증(myopathy), 근육퇴행위축(muscular dystrophy), 근육 손상(muscular injury), 근무력증(myasthenia), 근신경 전도성 질병(myoneural conductive disease), 신경 손상(nerve injury), 근위축성 축삭 경화증(amyotrophic lateral sclerosis, ALS), 긴장감퇴증(atony), 근경직증(myotonia), 악액질(cachexia) 등을 포함하는 의미로 해석될 수 있다.In the present invention, the muscle disease may be sarcopenia or muscular dystrophy. In the present invention, the sarcopenia or muscular atrophy is not only sarcopenia or muscular atrophy in the dictionary meaning, but also a muscle disease that causes or is induced by sarcopenia or muscular atrophy, such as sarcopenia and obesity. (sarcopenic obesity), myopathy, muscular dystrophy, muscular injury, myasthenia, myoneural conductive disease, nerve injury, muscular dystrophy It can be interpreted as meaning including amyotrophic lateral sclerosis (ALS), atony, myotonia, cachexia, and the like.
예를 들어, 상기 근위축증은 당뇨병성 근위축증(diabetic amyotrophy), 척수성 근위축증(spinal muscular atrophy) 등을 포함하는 의미일 수 있으며, 상기 근육퇴행위축은 Duchenne 근육퇴행위축(Duchenne muscular dystrophy), Becker 근육퇴행위축(Becker muscular dystrophy), 지대형 근육퇴행위축(limb girdle muscular dystrophy), 안면견갑상완 근육퇴행위축(facioscapulohumeral muscular dystrophy), 눈인두 근육퇴행위축(oculopharyngeal muscular dystrophy), 근육긴장 퇴행위축(Myotonic dystrophy) 등을 포함하는 의미일 수 있고, 상기 근육병증은 다발근염(polymyositis), 피부근염(dermatomyositis) 등의 염증성 근육병증(inflammatory myopathy), 내분비성 근육병증(endocrine myopathy), 독성 근육병증(toxic myopathy), 대사성 근육병증(metabolic myopathy), 사립체성 근육병증(mitochondrial myopathy), 선천성 근육병증(congenital myopathy) 등을 포함하는 의미일 수 있다.For example, the muscular dystrophy may include diabetic amyotrophy, spinal muscular atrophy, and the like, and the muscular dystrophy includes Duchenne muscular dystrophy and Becker muscular dystrophy. Becker muscular dystrophy, limb girdle muscular dystrophy, facioscapulohumeral muscular dystrophy, oculopharyngeal muscular dystrophy, myotonic dystrophy It may mean including the like, and the myopathy is inflammatory myopathy such as polymyositis and dermatomyositis, endocrine myopathy, and toxic myopathy , metabolic myopathy, mitochondrial myopathy, and congenital myopathy.
상기 약학 조성물은 케피어 유래 유산균 또는 이의 배양물을 유효성분으로서 함유하며, 통상의 방법에 따른 적절한 약제학적으로 허용되는 담체, 부형제 또는 희석제를 추가로 포함할 수 있다. 상기 약제학적으로 허용되는 담체는 제제시에 통상적으로 이용되는 것으로서, 락토스, 덱스트로스, 수크로스, 솔비톨, 만니톨, 전분, 아카시아 고무, 인산 칼슘, 알기네이트, 젤라틴, 규산 칼슘, 미세결정성 셀룰로스, 폴리비닐피롤리돈, 셀룰로스, 물, 시럽, 메틸 셀룰로스, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 활석, 스테아르산 마그네슘 및 미네랄 오일 등을 포함하나, 이에 한정되는 것은 아니다. The pharmaceutical composition contains kefir-derived lactic acid bacteria or a culture thereof as an active ingredient, and may further include an appropriate pharmaceutically acceptable carrier, excipient or diluent according to conventional methods. The pharmaceutically acceptable carrier is one commonly used in formulation, and includes lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia gum, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil, and the like.
본 발명의 약학 조성물은 상기 성분들 이외에 윤활제, 습윤제, 감미제, 향미제, 유화제, 현탁제, 보존제 등을 추가로 포함할 수 있다. 적합한 약제학적으로 허용되는 담체 및 제제화에 관해서는 레밍턴의 문헌[Remington's Pharmaceutical Sciences (19th ed., 1995)]에 개시되어 있는 방법을 이용하여 각 성분에 따라 바람직하게 제제화할 수 있다. The pharmaceutical composition of the present invention may further include lubricants, wetting agents, sweeteners, flavoring agents, emulsifiers, suspending agents, preservatives, and the like, in addition to the above components. Regarding suitable pharmaceutically acceptable carriers and formulations, it can be preferably formulated according to each component using the method disclosed in Remington's Pharmaceutical Sciences (19th ed., 1995).
본 발명의 약학 조성물은 경구 또는 비경구 투여 모두 가능하며, 비경구 투여는 정맥내 주입, 피하 주입, 근육 주입, 복강 주입, 경피 투여 등을 포함한다. The pharmaceutical composition of the present invention can be administered either orally or parenterally, and parenteral administration includes intravenous injection, subcutaneous injection, intramuscular injection, intraperitoneal injection, transdermal administration, and the like.
경구 투여용 제형으로는 예를 들면 정제, 환제, 경질, 연질 캅셀제, 액제, 현탁제, 유화제, 시럽제, 과립제 등이 있는데, 이들 제형은 유효성분 이외에 희석제(예: 락토즈, 덱스트로즈, 수크로즈, 만니톨, 솔비톨, 셀룰로즈 및/또는 글리신), 활택제(예: 실리카, 탈크, 스테아르산 및 그의 마그네슘 또는 칼슘염 및/또는 폴리에틸렌 글리콜)를 추가로 포함할 수 있다. 또한, 상기 정제는 마그네슘 알루미늄 실리케이트, 전분 페이스트, 젤라틴, 트라가칸스, 메틸셀룰로즈, 나트륨 카복시메틸셀룰로즈 및/또는 폴리비닐피롤리딘과 같은 결합제를 함유할 수 있으며, 경우에 따라 전분, 한천, 알긴산 또는 그의 나트륨 염과 같은 붕해제 또는 비등 혼합물 및/또는 흡수제, 착색제, 향미제 및 감미제를 함유할 수 있다. 상기 제형은 통상적인 혼합, 과립화 또는 코팅 방법에 의해 제조될 수 있다.Formulations for oral administration include, for example, tablets, pills, hard and soft capsules, solutions, suspensions, emulsifiers, syrups, granules, etc. chlorose, mannitol, sorbitol, cellulose and/or glycine), lubricants such as silica, talc, stearic acid and magnesium or calcium salts thereof and/or polyethylene glycol. In addition, the tablet may contain a binder such as magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidine, and in some cases starch, agar, alginic acid or a disintegrant or effervescent mixture, such as its sodium salt, and/or absorbents, colorants, flavors, and sweeteners. The formulation may be prepared by conventional mixing, granulating or coating methods.
또한, 비경구 투여용 제형의 대표적인 것은 주사용 제제이며, 주사용 제제의 용매로서 물, 링거액, 등장성 생리 식염수 또는 현탁액을 들 수 있다. 상기 주사용 제제의 멸균 고정 오일은 용매 또는 현탁 매질로서 사용할 수 있으며 모노-, 디-글리세라이드를 포함하여 어떠한 무자극성 고정오일도 이러한 목적으로 사용될 수 있다. 또한, 상기 주사용 제제는 올레산과 같은 지방산을 사용할 수 있다.In addition, a typical formulation for parenteral administration is an injection formulation, and water, Ringer's solution, isotonic physiological saline or suspension may be mentioned as a solvent for the injection formulation. Sterile fixed oils of the above injectable preparations may be used as a solvent or suspension medium, and any bland fixed oil may be used for this purpose, including mono- and di-glycerides. In addition, the formulation for injection may use a fatty acid such as oleic acid.
본 발명에 따른 조성물은 약학적으로 유효한 양으로 투여한다. 본 발명에 있어서, "약학적으로 유효한 양"은 의학적 치료에 적용 가능한 합리적인 수혜/위험 비율로 질환을 치료하기에 충분한 양을 의미하며, 유효 용량 수준은 환자의 질환의 종류, 중증도, 약물의 활성, 약물에 대한 민감도, 투여 시간, 투여 경로 및 배출 비율, 치료기간, 동시 사용되는 약물을 포함한 요소 및 기타 의학 분야에 잘 알려진 요소에 따라 결정될 수 있다. 본 발명에 따른 조성물은 개별 치료제로 투여하거나 다른 치료제와 병용하여 투여될 수 있고 종래의 치료제와는 순차적 또는 동시에 투여될 수 있으며, 단일 또는 다중 투여될 수 있다. 상기한 요소들을 모두 고려하여 부작용 없이 최소한의 양으로 최대 효과를 얻을 수 있는 양을 투여하는 것이 중요하며, 이는 통상의 지식을 가진 기술자에 의해 용이하게 결정될 수 있다.The composition according to the present invention is administered in a pharmaceutically effective amount. In the present invention, "pharmaceutically effective amount" means an amount sufficient to treat a disease with a reasonable benefit / risk ratio applicable to medical treatment, and the effective dose level is based on the type, severity, and activity of the drug of the patient's disease , sensitivity to the drug, time of administration, route of administration and excretion rate, duration of treatment, factors including drugs used concurrently, and other factors well known in the medical field. The composition according to the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, may be administered sequentially or simultaneously with conventional therapeutic agents, and may be administered single or multiple times. Considering all of the above factors, it is important to administer an amount that can obtain the maximum effect with the minimum amount without side effects, which can be easily determined by a person skilled in the art.
구체적으로, 본 발명에 따른 조성물의 유효량은 환자의 나이, 성별, 체중에 따라 달라질 수 있으며, 일반적으로는 체중 1kg 당 0.001 내지 150mg, 바람직하게는 0.01 내지 100mg을 매일 또는 격일 투여하거나 1일 1 내지 3회로 나누어 투여할 수 있다. 그러나 투여 경로, 성별, 체중, 연령 등에 따라서 증감될 수 있으므로 상기 투여량이 어떠한 방법으로도 본 발명의 범위를 한정하는 것은 아니다.Specifically, the effective amount of the composition according to the present invention may vary depending on the patient's age, sex, and weight, and is generally 0.001 to 150 mg per 1 kg of body weight, preferably 0.01 to 100 mg daily or every other day, or 1 to 1 per day. It can be divided into 3 doses. However, since it may increase or decrease depending on the route of administration, gender, weight, age, etc., the dosage is not limited to the scope of the present invention in any way.
실시예Example
이하, 실시예를 통하여 본 발명을 더욱 상세히 설명하고자 한다. 이들 실시예는 오로지 본 발명을 예시하기 위한 것으로, 본 발명의 범위가 이들 실시예에 의해 제한되는 것으로 해석되지는 않는다는 것은 당업계에서 통상의 지식을 가진 자에게 있어서 자명할 것이다.Hereinafter, the present invention will be described in more detail through examples. These examples are only for exemplifying the present invention, and it will be apparent to those skilled in the art that the scope of the present invention is not to be construed as being limited by these examples.
실험 준비: 케피어 유래 유산균 전배양Experimental Preparation: Kefir-derived Lactobacillus Preculture
케피어 유래 유산균을 MRS 고체배지(Man Rogosa Sharpe(MRS) agar)에 평판도말(spreading)하여 37℃에서 48시간 동안 전배양하였다. Kefir-derived lactic acid bacteria were pre-cultured at 37° C. for 48 hours by spreading on MRS solid medium (Man Rogosa Sharpe (MRS) agar).
케피어 유래 유산균으로는 락토바실러스 케피어리 DH5(이하, "DH5"), 류코노스톡 메센테로이데스 LCM4(이하, "Leuc4") 및 류코노스톡 메센테로이데스 LCM8(이하, "Leuc8")을 이용하였다. 상기 DH5는 한국미생물보존센터에 수탁번호 KCCM11837P(수탁일자: 2016년 4월 29일)로 기탁되어 있으며, LCM4는 한국미생물보존센터에 수탁번호 KCCM12117P(수탁일자: 2017년 9월 21일)로 기탁되어 있으며, LCM8은 한국생명공학연구원에 수탁번호 KCTC18854P(수탁일자: 2020년 10월 16일)로 기탁되어 있다.Kefir-derived lactic acid bacteria include Lactobacillus kefir DH5 (hereinafter "DH5"), Leuconostoc mesenteroides LCM4 (hereinafter "Leuc4") and Leuconostoc mesenteroides LCM8 (hereinafter "Leuc8") were used. The above DH5 was deposited with the Korea Microorganism Conservation Center under the accession number KCCM11837P (date of accession: April 29, 2016), and LCM4 was deposited with the Korea Center for Microorganism Conservation under the accession number KCCM12117P (date of accession: September 21, 2017) and LCM8 has been deposited with the Korea Research Institute of Bioscience and Biotechnology under the accession number KCTC18854P (date of accession: October 16, 2020).
전배양된 유산균을 각 실험예의 방법에 따라 배지에 접종하여 본배양한 후 실험에 사용하였다.The pre-cultured lactic acid bacteria were inoculated into the medium according to the method of each experimental example, and then used for the experiment after main culture.
실험 방법: 근육세포에 대한 활성 시험 방법Test method: Test method for activity on muscle cells
도 1에 나타낸 바와 같이, 세포 배양용 웰 플레이트에 C2C12 세포를 분주(seeding)하고 4 내지 5일간 분화를 유도한 후 DMEM(Dulbecco's modified Eagle's medium)에서 2시간 동안 배양하였다. As shown in FIG. 1, C2C12 cells were seeded in a well plate for cell culture, and differentiation was induced for 4 to 5 days, followed by culturing in DMEM (Dulbecco's modified Eagle's medium) for 2 hours.
그 후, 팔미트산(palmitic acid, PA)을 이소프로필알코올(isopropyl alcohol)에 녹인 용액 및/또는 각 실험예에 따른 샘플을 처리한 다음 24시간 후 근섬유의 수, 길이 및 지름을 측정하거나 근육의 분화 또는 위축 인자의 발현량을 측정하여 활성을 시험하였다.Then, a solution of palmitic acid (PA) dissolved in isopropyl alcohol And / or after processing the samples according to each experimental example, the activity was tested by measuring the number, length and diameter of muscle fibers or measuring the expression level of muscle differentiation or atrophy factors after 24 hours.
실험예 1: PA 및 케피어 유래 유산균의 세포독성(cytotoxicity) 확인Experimental Example 1: Confirmation of cytotoxicity of PA and kefir-derived lactic acid bacteria
PA 및 케피어 유래 유산균의 세포독성을 확인하기 위하여, C2C12 세포를 배양하고 각 물질을 농도별로 처리하여 MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay를 수행하였다. In order to confirm the cytotoxicity of PA and kefir-derived lactic acid bacteria, C2C12 cells were cultured and each substance was treated by concentration to perform MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay was performed.
MTT assay를 진행하기 전 C2C12 세포를 분화시키기 위하여 3.0 x 104 cells/well로 96 well plate에 seeding하고 분화배지(differentiation medium)로 교체 후 2~4일간 37℃ 인큐베이터에서 배양하였다. 세포가 배양중인 96 well plate에 처리할 샘플들과 PBS를 20㎕씩 분주한 후 24시간 동안 다시 배양시켰다. In order to differentiate C2C12 cells before proceeding with the MTT assay, 3.0 x 10 4 cells/well were seeded in a 96 well plate, replaced with a differentiation medium, and cultured in a 37 °C incubator for 2-4 days. Samples to be treated and 20 μl of PBS were dispensed into each 96-well plate in which cells were cultured, and cultured again for 24 hours.
24시간이 지난 후, 5mg/mL의 MTT를 PBS에 녹여 준비하고 25분 동안 초음파 처리(sonication)를 진행하여 잘게 부순 다음, 0.2㎛의 필터로 필터링하고, 차광 보관하였다. 그 후 96 well plate에 well 당 20㎕ 분주하고, 4시간 배양하였다. 다음으로, 96 well plate 자체를 원심분리(1,500rpm, 5분)한 후, 상층액을 제거하여 밑에 붙은 샘플과 세포의 상태를 유지시켰다. 그 후 멀티 피펫으로 DMSO를 well 당 150㎕ 넣고 상온에서 15분 배양하였다. After 24 hours, 5 mg/mL of MTT was prepared by dissolving it in PBS, and sonicated for 25 minutes to break it into small pieces, filtered through a 0.2 μm filter, and stored in a light-shielded manner. After that, 20 μl was dispensed per well in a 96 well plate and cultured for 4 hours. Next, after the 96 well plate itself was centrifuged (1,500 rpm, 5 minutes), the supernatant was removed to maintain the state of the sample and cells attached to the bottom. Then, 150 μl of DMSO was added per well with a multi-pipette and incubated for 15 minutes at room temperature.
마지막으로 흡광도 측정을 통해 세포의 생존율을 계산하였다. 흡광도는 540nm 조건으로 측정하였고, 마지막 column 분주 시 타이머를 맞추고 15분 후 측정하였다. 세포 생존률은 아래 식에 따라 계산하였으며, 80% 기준으로 세포 생존성(cell viability)을 판단하였다.Finally, cell viability was calculated by measuring absorbance. Absorbance was measured under the condition of 540 nm, and was measured 15 minutes after setting the timer at the time of the last column dispensing. Cell viability was calculated according to the formula below, and cell viability was determined based on 80%.
세포 생존률 (%) = (Asample - Ablank) / (Acontrol - Ablank) x 100Cell viability (%) = (A sample - A blank ) / (A control - A blank ) x 100
도 2는 PA의 세포독성을 평가하기 위한 MTT assay 결과를 나타낸 것이다. 도 2를 참조하면, PA 농도 80mM까지 세포수가 유지되고, 농도가 그 이상인 경우 세포수가 감소하는 것을 확인할 수 있다.Figure 2 shows the MTT assay results for evaluating the cytotoxicity of PA. Referring to FIG. 2, it can be seen that the cell number is maintained up to a PA concentration of 80 mM, and the cell number decreases when the concentration is higher than that.
도 3은 케피어 유래 유산균의 세포독성을 평가하기 위한 MTT assay 결과를 나타낸 것이다. 도 3을 참조하면, 케피어 유래 유산균인 DH5, Leuc4 및 Leuc8의 농도 1 x 108, 1 x 107 및 1 x 106 CFU/ml에서 모두 세포수가 유지되는 것을 확인할 수 있다.Figure 3 shows the MTT assay results for evaluating the cytotoxicity of kefir-derived lactic acid bacteria. Referring to FIG. 3 , it can be seen that the number of cells is maintained at concentrations of 1 x 10 8 , 1 x 10 7 and 1 x 10 6 CFU/ml of kefir-derived lactic acid bacteria, DH5, Leuc4 and Leuc8.
실험예 2: 케피어 유래 유산균 처리에 따른 C2C12 근육세포 변화 분석Experimental Example 2: C2C12 muscle cell change analysis according to kefir-derived lactic acid bacteria treatment
케피어 유래 유산균의 근육 보호 및 증강 효과를 확인하기 위하여 도 1의 방법과 같이 PA 용액으로 근육세포에 근감소를 유도하고, 유산균 처리 여부에 따른 근육세포 형태 변화를 관찰하였다.In order to confirm the muscle protection and enhancing effects of kefir-derived lactic acid bacteria, muscle reduction was induced in muscle cells with PA solution as in the method of FIG.
유산균 샘플로는 전배양된 유산균 DH5 및 Leuc4를 각각 MRS 액체배지(1 L 당 Peptone No.3 10g, Beef extract 10g, Yeast extract 5g, Dextrose 20g, Polysorbate 80 1g, Ammonium Citrate 2g, Sodium acetate 5g, Magnesium sulfate 0.1g, Manganese sulfate 0.05g, Dipotassium phosphate 2g, pH 6.5)에 1 x 108 CFU/ml 접종한 후 48시간(또는 1 x 105 CFU/ml 접종 후 96시간) 배양시켜 활성화한 뒤 열처리로 사균화(heat kill)한 샘플(균수: 2 x 109 CFU/mL)을 이용하였다. 구체적으로 샘플의 heat kill은 2 x 109 CFU/mL까지 배양한 균마다 탁도를 맞춰 멸균생리식염수를 첨가해주고, Inactivation을 진행하기 위해 70℃ water bath에 30분간 넣어둔 후 4℃, 3000rpm에서 10분간 원심 분리함으로써 수행하였다. As lactic acid bacteria samples, pre-cultured lactic acid bacteria DH5 and Leuc4 were mixed in MRS liquid medium (Peptone No.3 10g per 1 L, Beef extract 10g, Yeast extract 5g, Dextrose 20g,
그 후 상층액을 버리고 새로운 생리식염수를 넣어 피펫팅을 해주는 방식을 2~3회 반복하고, 각각의 균 수에 맞추어 생리식염수를 넣어준 후 -80℃에 2일 이상 냉동시켜 동결건조를 준비하였다. 이 후 동결건조한 샘플은 세포실험을 진행할 때 세포 배지에 녹여서 일정량 투여시켰다.After that, the supernatant was discarded, new physiological saline was added, pipetting was repeated 2 to 3 times, physiological saline was added according to the number of bacteria, and then frozen at -80 ° C for more than 2 days to prepare freeze-drying. . Thereafter, the lyophilized sample was dissolved in a cell medium and administered in a certain amount during the cell experiment.
비교를 위하여, PA 없이 PBS만 처리한 대조군(Con) 및 PA와 함께 유산균 샘플 대신 인산완충생리식염수(phosphate buffer saline, PBS)를 처리한 대조군(PA)에 대해서도 동일한 방법으로 실험을 수행하였다.For comparison, experiments were performed in the same manner for a control group (Con) treated only with PBS without PA and a control group (PA) treated with phosphate buffered saline (PBS) instead of lactic acid bacteria samples with PA.
각 그룹에 대한 설명을 아래 표 1에 나타내었으며, 실험 후 각 그룹을 현미경으로 관찰하고, 근섬유(myotube)의 수(count), 길이(length) 및 직경(diameter)을 측정하였다.A description of each group is shown in Table 1 below. After the experiment, each group was observed under a microscope, and the number (count), length (length) and diameter (diameter) of myotubes were measured.
도 4는 각 그룹에 대한 현미경 분석 결과로서 x40 배율(a) 및 x100 배율(b) 이미지를 나타낸 것이다. 도 4을 통해, PA 및 PBS를 처리한 그룹(PA)의 경우 PBS만 처리한 그룹(Con)에 비해 근세포가 상당히 손상된 반면, PA와 함께 케피어 유래 유산균을 처리한 그룹(DH5 및 Leuc4)은 근세포의 손상이 적게 관찰되는 것을 확인하였다. 4 shows x40 magnification (a) and x100 magnification (b) images as a result of microscopic analysis for each group. 4, in the case of the PA and PBS-treated group (PA), myocytes were significantly damaged compared to the PBS-only group (Con), whereas the groups treated with PA and kefir-derived lactic acid bacteria (DH5 and Leuc4) It was confirmed that less damage to myocytes was observed.
도 5는 근섬유의 수(a), 길이(b) 및 직경(c) 측정 결과를 나타낸 것으로, 도 5의 결과를 통해, PA와 함께 케피어 유래 유산균을 처리한 그룹(DH5 및 Leuc4)이 PA 및 PBS를 처리한 그룹(PA)에 비해 근섬유의 수, 길이 및 직경의 측정값이 더 큰 것을 확인하였다. 그 중에서도, DH5 그룹이 Leuc4 그룹에 비하여 근섬유의 수, 길이 및 직경의 측정값이 더 높은 결과가 나타났다.Figure 5 shows the results of measuring the number (a), length (b) and diameter (c) of muscle fibers. Through the results of Figure 5, the group (DH5 and Leuc4) treated with PA and kefir-derived lactic acid bacteria showed that the PA And compared to the group (PA) treated with PBS, it was confirmed that the measured values of the number, length, and diameter of muscle fibers were greater. Among them, the DH5 group showed higher measured values of the number, length, and diameter of muscle fibers than the Leuc4 group.
이에 따라, 케피어 유래 유산균이 근육을 보호하고 증강시키는 효과를 나타낸다는 것을 확인할 수 있었으며, 락토바실러스 케피어리의 효과가 류코노스톡 메센테로이데스보다 더 우수하다는 것을 확인할 수 있었다.Accordingly, it was confirmed that kefir-derived lactic acid bacteria exhibited an effect of protecting and enhancing muscles, and it was confirmed that the effect of Lactobacillus kefir was superior to that of Leuconostoc mesenteroides.
실험예 3: 케피어 유래 유산균 처리에 따른 근육 관련 인자 qPCR 분석Experimental Example 3: qPCR analysis of muscle-related factors according to kefir-derived lactic acid bacteria treatment
실험예 2의 방법으로 C2C12 세포에 PA 및 유산균 샘플을 처리하고, 근육 관련 인자인 MyoD 및 Atrogin-1에 대해 qPCR을 수행한 후 그 결과를 도 6 및 도 7에 나타내었다.After treating PA and lactic acid bacteria samples in C2C12 cells by the method of Experimental Example 2, and performing qPCR for muscle-related factors MyoD and Atrogin-1, the results are shown in FIGS. 6 and 7 .
도 6은 MyoD에 대한 실험 결과를 나타낸 것으로, 도 6을 통해, PA와 및 PBS를 처리한 그룹(PA)에 비해 PA와 함께 락토바실러스 케피어리 DH5를 처리한 그룹(DH5)에서 MyoD의 발현이 소폭 증가한 것을 확인할 수 있었다. 이에 따라, 케피어 유래 유산균인 락토바실러스 케피어리 DH5가 근세포 분화 및 성숙에도 긍정적인 효과를 보인다는 것을 확인할 수 있었다. Figure 6 shows the experimental results for MyoD, and through Figure 6, the expression of MyoD in the group treated with PA and Lactobacillus kefir DH5 (DH5) compared to the group treated with PA and PBS (PA). A slight increase was observed. Accordingly, it was confirmed that the kefir-derived lactic acid bacteria, Lactobacillus kefirii DH5, showed a positive effect on myocyte differentiation and maturation.
도 7은 Atrogin-1에 대한 실험 결과를 나타낸 것으로, 도 7을 통해, PA 및 PBS를 처리한 그룹(PA)에 비해 PA와 함께 케피어 유래 유산균을 처리한 그룹(DH5 및 Leuc4)에서 근섬유 위축의 마커인 Atrogin-1이 유의적으로 감소한 것을 확인하였다. 이에 따라, 케피어 유래 유산균이 근감소로부터 근육을 보호하는 효과가 있음을 확인할 수 있었다. Figure 7 shows the experimental results for Atrogin-1, and through Figure 7, muscle fiber atrophy in the group treated with PA and lactic acid bacteria derived from kefir (DH5 and Leuc4) compared to the group treated with PA and PBS (PA) It was confirmed that Atrogin-1, a marker of , was significantly decreased. Accordingly, it was confirmed that the kefir-derived lactic acid bacteria had the effect of protecting muscles from muscle loss.
실험예 4: 케피어 유래 유산균 배양물 처리에 따른 C2C12 근육세포 변화 분석 Experimental Example 4: C2C12 muscle cell change analysis according to kefir-derived lactic acid bacteria culture treatment
케피어 유래 유산균 배양물의 근육 보호 및 증강 효과를 확인하기 위하여 도 1의 방법과 같이 PA로 근육세포에 근감소를 유도하고, 배양물 처리 여부에 따른 근육세포 형태 변화를 관찰하였다.In order to confirm the muscle protection and enhancing effect of the kefir-derived lactic acid bacteria culture, muscle reduction was induced in muscle cells with PA as in the method of FIG. 1, and changes in muscle cell morphology were observed depending on whether or not the culture was treated.
전배양된 유산균 DH5를 유청(whey) 배지에 1 x 108 CFU/ml 접종하고 48시간(또는 1 x 105 CFU/ml 접종하고 96시간) 배양시켜 2 x 109 CFU/mL의 배양액을 얻은 후, 3,134 x g의 속도로 10분간 원심 분리하여 균체는 버리고 상등액을 수거한 후에 0.45㎛ pore-size로 필터링하여 수득한 배양물 샘플을 이용하였다. The pre-cultured lactobacillus DH5 was inoculated in whey medium at 1 x 10 8 CFU/ml and cultured for 48 hours (or 1 x 10 5 CFU/ml after inoculation for 96 hours) to obtain a culture medium of 2 x 10 9 CFU/mL. Then, the cells were centrifuged at a speed of 3,134 x g for 10 minutes, the cells were discarded, the supernatant was collected, and the culture sample obtained by filtering with a 0.45 μm pore-size was used.
비교를 위하여, PA 없이 PBS만 처리한 대조군(Con) 및 PA와 함께 배양물 샘플 대신 PBS를 처리한 대조군(PA)에 대해서도 동일한 방법으로 실험을 수행하였다.For comparison, experiments were performed in the same manner for a control group (Con) treated with only PBS without PA and a control group (PA) treated with PBS instead of the culture sample with PA.
각 그룹에 대한 설명을 아래 표 2에 나타내었으며, 실험 후 각 그룹을 현미경으로 관찰하고, 근섬유(myotube)의 수(count), 길이(length) 및 직경(diameter)을 측정하였다.A description of each group is shown in Table 2 below. After the experiment, each group was observed under a microscope, and the number (count), length (length) and diameter (diameter) of myotubes were measured.
도 8은 각 그룹에 대한 현미경 분석 결과로서 x40 배율(a) 및 x100 배율(b) 이미지를 나타낸 것이다. 도 8을 참조하면, PA 및 PBS를 처리한 그룹(PA)의 경우 PBS만 처리한 그룹(Con)에 비해 근세포가 손상된 것을 확인할 수 있다. 반면, PA와 함께 케피어 유래 유산균의 배양물을 처리한 그룹(Po5)은 근손상이 거의 관찰되지 않았으며, 이로부터 케피어 유래 유산균의 배양물이 근세포를 보호하는 효과가 있음을 확인할 수 있었다.8 shows x40 magnification (a) and x100 magnification (b) images as a result of microscopic analysis for each group. Referring to FIG. 8 , in the case of the group treated with PA and PBS (PA), it can be seen that myocytes are damaged compared to the group treated only with PBS (Con). On the other hand, in the group (Po5) treated with the culture of kefir-derived lactic acid bacteria along with PA, almost no muscle damage was observed, and it was confirmed that the culture of kefir-derived lactic acid bacteria had the effect of protecting myocytes. .
도 9는 근섬유의 수(a), 길이(b) 및 직경(c) 측정 결과를 나타낸 것으로, 도 9를 통해 PA와 함께 케피어 유래 유산균의 배양물을 처리한 그룹(Po5)의 경우 PA 및 PBS를 처리한 그룹(PA)에 비해 근섬유의 수, 길이 및 직경의 측정값이 모두 클 뿐만 아니라, PBS만 처리한 정상 그룹(Con)과 유사한 수준으로 나타나는 것을 확인하였다.Figure 9 shows the results of measuring the number (a), length (b), and diameter (c) of muscle fibers. In the case of the group (Po5) treated with PA and the culture of kefir-derived lactic acid bacteria, PA and Compared to the PBS-treated group (PA), the measured values of the number, length, and diameter of muscle fibers were all larger, and it was confirmed that they appeared at similar levels to the normal group (Con) treated only with PBS.
이에 따라, 케피어 유래 유산균의 배양물의 근육 보호 및 증강 효과가 매우 우수하다는 것을 확인할 수 있었다.Accordingly, it was confirmed that the muscle protection and enhancing effect of the culture of kefir-derived lactic acid bacteria was very excellent.
실험예 5: 케피어 유래 유산균 배양물 처리에 따른 근육 관련 인자 qPCR 분석Experimental Example 5: qPCR analysis of muscle-related factors according to kefir-derived lactic acid bacteria culture treatment
실험예 4의 방법으로 C2C12 세포에 PA 및 유산균의 배양물을 처리하고, 근육 관련 인자인 MyoD 및 Atrogin-1에 대해 qPCR을 수행한 후 그 결과를 도 10 및 도 11에 나타내었다. After treating cultures of PA and lactic acid bacteria in C2C12 cells by the method of Experimental Example 4, performing qPCR for muscle-related factors MyoD and Atrogin-1, the results are shown in FIGS. 10 and 11 .
도 10은 MyoD에 대한 실험 결과를 나타낸 것으로, 도 10을 참조하면, PA와 함께 PBS를 처리한 그룹(PA)에 비해 케피어 유래 유산균의 배양물을 처리한 그룹(Po5)에서 근육의 분화 및 성숙의 마커인 MyoD의 발현이 유의적으로 증가하였으며, PBS만 처리한 정상 그룹(Con)의 수치와 비슷한 수준에 도달한 것을 보였다. 이에 따라, 케피어 유래 유산균 배양물이 근세포 분화 및 성숙에 긍정적인 효과를 보인다는 것을 확인할 수 있었다.Figure 10 shows the experimental results for MyoD. Referring to Figure 10, differentiation and muscle differentiation and The expression of MyoD, a marker of maturation, was significantly increased and reached a level similar to that of the normal group (Con) treated only with PBS. Accordingly, it was confirmed that the kefir-derived lactic acid bacteria culture showed a positive effect on myocyte differentiation and maturation.
도 11은 Atrogin-1에 대한 실험 결과를 나타낸 것으로, 도 11의 결과로부터 PA 및 PBS를 처리한 그룹(PA)에 비해 PA와 함께 케피어 유래 유산균의 배양물을 처리한 그룹(Po5)에서 근섬유 위축의 마커인 Atrogin-1이 유의적으로 감소한 것을 확인하였다. 이에 따라, 케피어 유래 유산균 배양물이 근감소를 억제하는 근육 보호 효과가 있다는 것을 확인할 수 있었다.Figure 11 shows the experimental results for Atrogin-1, and from the results of Figure 11, compared to the group treated with PA and PBS (PA), muscle fibers in the group treated with PA and the culture of kefir-derived lactic acid bacteria (Po5) It was confirmed that Atrogin-1, a marker of atrophy, was significantly decreased. Accordingly, it was confirmed that the kefir-derived lactic acid bacteria culture has a muscle protective effect that inhibits muscle loss.
이상으로 본 발명의 내용의 특정부분을 상세히 기술하였는 바, 당업계의 통상의 지식을 가진 자에게 있어서, 이러한 구체적 기술은 단지 바람직한 실시 양태일 뿐이며, 이에 의해 본 발명의 범위가 제한되는 것이 아닌 점은 명백할 것이다. As above, specific parts of the content of the present invention have been described in detail, and for those skilled in the art, these specific descriptions are only preferred embodiments, and the scope of the present invention is not limited thereby. It will be clear.
Claims (5)
A functional food for muscle enhancement or protection comprising kefir-derived lactic acid bacteria or a culture thereof.
상기 케피어 유래 유산균이 락토바실러스 케피어리(Lactobacillus kefiri) 및 류코노스톡 메센테로이데스(Leuconostoc mesenteroides)로부터 선택된 1종 이상인, 근육 증강 또는 보호용 기능성 식품.
According to claim 1,
The kefir-derived lactic acid bacteria are Lactobacillus kefiri ( Lactobacillus kefiri ) and Leuconostoc mesenteroides ( Leuconostoc mesenteroides ) At least one selected from, muscle strengthening or protective functional food.
상기 케피어 유래 유산균의 배양물이 케피어 유래 유산균을 배지에 접종한 후 배양하고 균체를 제거하여 수득한 것인, 근육 증강 또는 보호용 기능성 식품.
According to claim 1,
The culture of the kefir-derived lactic acid bacteria is obtained by inoculating the kefir-derived lactic acid bacteria in a medium and then culturing and removing the cells, a functional food for muscle enhancement or protection.
상기 배지가 MRS (Man Rogosa Sharpe), GAM (Gifu Anaerobic Medium), 유청 및 탈지유로 구성된 군에서 선택된 1종 이상의 배지를 포함하는, 근육 증강 또는 보호용 기능성 식품.
According to claim 3,
Wherein the medium is MRS (Man Rogosa Sharpe), GAM (Gifu Anaerobic Medium), containing at least one medium selected from the group consisting of whey and skim milk, functional food for muscle enhancement or protection.
A pharmaceutical composition for the prevention or treatment of sarcopenia or muscular dystrophy comprising kefir-derived lactic acid bacteria or a culture thereof.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020210190330 | 2021-12-28 | ||
| KR20210190330 | 2021-12-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20230100546A true KR20230100546A (en) | 2023-07-05 |
Family
ID=87158687
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020220044689A KR20230100546A (en) | 2021-12-28 | 2022-04-11 | Composition for Enhancing or Protecting Muscle Comprising Lactic Acid Bacteria from Kefir or Cultured Product Thereof |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20230100546A (en) |
-
2022
- 2022-04-11 KR KR1020220044689A patent/KR20230100546A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11268064B2 (en) | Lactobacillus rhamnosus RHT-3201 conjugated to polysaccharide polymer binder, and use thereof for prevention or treatment of atopic diseases | |
| US9750775B2 (en) | Lactic acid bacterium-containing preparation | |
| US9387228B2 (en) | Agent for prevention or amelioration of obesity | |
| KR101426275B1 (en) | The composition containing combination of 5 probiotics which have efficacy preventing fatty acid synthesis and promoting fatty acid oxidation as an effective factor | |
| KR20200128501A (en) | Nanovesicles from Adult Stem Cells and its use for targeted therapy | |
| KR20150110378A (en) | Composition comprising extract post-fermented tea | |
| KR20200084817A (en) | Novel Lactobacillus rhamnosus strain for preventing or treating obesity and the use thereof | |
| KR102606952B1 (en) | Method of Lactobacillus Plantarum TWK10 composition for improving inflammation or reducing body fat after exercise | |
| KR102543494B1 (en) | Novel probiotics and use thereof | |
| US20220000943A1 (en) | Composition comprising tetragenococcus halophilus for prevetion or treatment of behcet's disease or herpes simplex virus infection | |
| KR102230517B1 (en) | Lactobacillus salivarius having anticariogenic activities and composition comprising the same | |
| KR102037108B1 (en) | Composition for Preventing or Treating Obesity Comprising Heat-killed Lactic Acid Bacteria or Yeast from Kefir | |
| KR102037897B1 (en) | Composition for Preventing or Treating Obesity Comprising Lactic Acid Bacteria from Kefir and Grape Seed Flour | |
| KR102479732B1 (en) | Limosilactobacillus reuteri MG5458 strain and composition for preventing, improving or treating alcoholic fatty liver comprising the same | |
| WO2011105403A1 (en) | Composition having bedsore-relieving effect | |
| KR20230100546A (en) | Composition for Enhancing or Protecting Muscle Comprising Lactic Acid Bacteria from Kefir or Cultured Product Thereof | |
| KR102210092B1 (en) | Lactobacillus reuteri MG505 having anticariogenic activities and composition comprising the same | |
| KR20240011435A (en) | Composition for Enhancing or Protecting Muscle Comprising Cultured Product of Lactic Acid Bacteria from Kefir Using Korean Melon Peel Extract Medium | |
| KR102502978B1 (en) | Composition for Anti-inflammation or Enhancing Immunity Comprising Surface Layer Protein of Lactic Acid Bacteria from Kefir | |
| KR101973514B1 (en) | Prebiotics Containing Grape seed flour | |
| KR102037898B1 (en) | Composition for Preventing or Treating Hepatic Steatosis Comprising Lactic Acid Bacteria from Kefir and Grape Seed Flour | |
| KR102217834B1 (en) | Composition for Preventing or Treating Obesity Comprising Heat-killed Lactic Acid Bacteria from Kefir and Grape Seed Flour | |
| CN114404459B (en) | Application of lactobacillus reuteri CCFM1135 in reducing plasma trimethylamine oxide | |
| US20200188453A1 (en) | Method of a lactobacillus plantarum twk10 composition for improving inflammation after exercise | |
| KR20230057194A (en) | Lactobacillus brevis MG5311 strain and composition for preventing, improving or treating alcoholic fatty liver comprising the same |